NCT06292286View on ClinicalTrials.gov

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

NARecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Recurrent Ovarian Carcinoma
Interventions
PROCEDURE

Carboplatin or cisplatin

Carboplatin of cisplatin for 3-6 cycles

DRUG

Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar

Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles

DRUG

Bevacizumab or biosimilar

Optional

PROCEDURE

Cytoreductive surgery

Cytoreductive surgery after chemotherapy

Trial Locations (1)

Unknown

RECRUITING

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER